IL-6-dependent changes in preclinical phase of arthritis in gp130F759.

Slides:

Advertisements

Similar presentations

The genomic region spanning rs shows enhancer activity.

Advertisements

Multivariable model of abatacept retention in biologic-naïve patients.

Receiver operating characteristic (ROC) curves: rapid radiographic progression prognosis by anticyclic citrullinated peptides generation 2 antibodies (anti-CCP2),

Multivariable model of abatacept retention by RF and anti-CCP status in biologic-naïve patients with or without radiographic erosion at baseline. Multivariable.

(A) EULAR response based on DAS28 (ESR, otherwise CRP) and (B) Boolean remission, at 6 months in patients treated with abatacept as a first-line biologic.

Naïve B cells (CD19+CD27-), memory B cells (CD19+CD27+) and plasmablasts (PB CD27++) levels in patients with systemic sclerosis. Indicated points resemble.

Mature and immature NGF forms in patients with JIA and RA

Conversion to ACPA and RF seronegative status in patients with early RA treated with abatacept+MTX compared with MTX alone. Conversion to ACPA and RF seronegative.

MFS1 expression in parental and progeny strains.

Changes in evaluation indicators from baseline to 12 weeks per visit.

Kaplan-Meier survival plots for survival without: (A) progression to RA according to the number of joints with significant synovitis defined by GS≥ grade.

Percentage of patients achieving EULAR response

p75NTR, TrkA and sortilin expression levels in patients with JIA

Endochondral bone formation in HLA-B27 transduced ATDC5 micromasses.

Association of disease parameters at the time of methotrexate reinitiation during the OLE based on propensity score matching. Association of disease parameters.

Cells and mediators of the immune-inflammatory ‘cascade’ leading to overt clinical rheumatoid arthritis are described. Cells and mediators of the immune-inflammatory.

The patient profiles presented to rheumatologists in the discrete choice experiment (DCE). aCCP, anti-cyclic citrullinated peptide; DAS28, 28-joint Disease.

Frequency of patients in flare at each time point over 3 months

The landscape of cytokine-producing CD4 T cell populations in the peripheral blood (PB) and in the joints. Venn diagrams show the frequency of overlapping.

Conventional treatment to prevent obstetric complications during pregnancy. *Antiphospholipid (aPL) antibody carriers: individuals with aPL positivity.

P75NTR and disease severity (A) in persistent oligoarticular (n=29), extended oligoarticular (n=16) and polyarticular (n=13) patients p75NTR mRNA expression.

The severity of fatigue over 8 years of disease in early rheumatoid arthritis patients. The severity of fatigue over 8 years of disease in early rheumatoid.

OR for baseline predictors of MDA at weeks 12, 24, 48, 96 and 144 by univariate analysis of observed data. OR for baseline predictors of MDA at weeks 12,

Cumulative probability of time to achieve first sustained DAS28 (CRP) remission by conversion to ACPA seronegative status. Cumulative probability of time.

(A) Reduction of circulating stromal cell-derived factor (SDF)-1 levels over time in patients with rheumatoid arthritis (RA) and ankylosing spondylitis.

Different treatment strategies in rheumatoid arthritis in relation to radiographic progression (A) number of swollen joints (B) and fatigue severity over.

DAS28-CRP cut-off values corresponding to the DAS28-ESR cut-off values for remission, LDA and HDA, average of three statistical approaches. DAS28-CRP cut-off.

IFN and neutrophil gene expression studies.

Changes in microRNA expression on treatment of RASF for 2 weeks with 20 mM L-methionine or betaine. Changes in microRNA expression on treatment of RASF.

Osteogenesis in monolayer HLA-B27 transduced hPDCs.

Fig. 1. Lack of Hmga1 and Hmga2 expression in A1/A2-KO mice

The association between alcohol consumption and the severity of MRI-detected inflammation in hand and foot joints of (A) patients with RA and (B) asymptomatic.

Matrix risk model showing the probability of SRP in patients with moderate disease activity after 3 years of MTX treatment. Matrix risk model showing the.

Multivariate analysis for SRP after 3 years in patients with moderate disease activity despite MTX treatment. Multivariate analysis for SRP after 3 years.

Relative impact of the different levels of education on the physical and mental components of SF-12 across the different chronic disorders. Relative impact.

The earliest pathological changes of arthritis in gp130F759 develop at 5 months of age. The earliest pathological changes of arthritis in gp130F759 develop.

Examples of MRI at presentation with clinically suspect arthralgia (CSA) (top panel) and at IA development (bottom panel), showing joints (A) from no inflammation.

The clinical and histological changes of arthritis in gp130F759.

Difference in the risk of MACEs in patients treated with anti-IL23 agents compared with the placebo in RCTs. IL, interleukin; MACEs, major adverse cardiovascular.

Relative treatment effects concerning efficacy endpoints in patients with inadequate response to methotrexate for triple therapy versus TNFi–methotrexate.

Cox proportional-hazards model of time to first RA flare after treatment withdrawal for patients who entered the re-treatment period (n=146). Cox proportional-hazards.

(A and B) Changes in the levels of DNA methyltransferases (DNMTs) transcripts on treatment of RASF for 2 weeks with 20 mM L-methionine (A) or betaine (B).

DAS28-CRP change from baseline over 24 weeks (TP1 per-protocol set) at baseline, the mean DAS28-CRP was 5.42 and 5.53 for GP2015 and ETN groups, respectively.

Least squares mean changes from baseline (and 95% CIs) at month three for (A) HAQ-DI, (B) FACIT-F and (C) SF-36 physical functioning domain observed in.

Increased anti-DNA Abs in 2KO-Bcl6TC mice.

The effect of 3,4-dichloropropionaniline (DCPA) treatment on collagen-induced arthritis (CIA) at 40 days. The effect of 3,4-dichloropropionaniline (DCPA)

Study design. *Randomisation stratified by corticosteroid use at baseline. Study design. *Randomisation stratified by corticosteroid use at baseline. DAS28-CRP,

Satisfaction with control of RA

The proportions (and 95% CIs) of anti-CCP+/RF+, anti-CCP+/RF- anti-CCP-/RF+ and anti-CCP-/RF- patients receiving tofacitinib 5 or 10 mg two times a day.

The proportions (and 95% CIs) of anti-CCP+/RF+, anti-CCP+/RF-, anti-CCP-/RF+ and anti-CCP-/RF- patients receiving tofacitinib 5 or 10 mg two times a day.

Changes in levels of transcripts encoding inflammatory cytokines and GFAP. The amounts of the PCR cDNA products were obtained from phosphorimager readings.

Schematic depiction of categories of inflammation in 350 small joints during progression from clinically suspect arthralgiato inflammatory arthritis. Schematic.

Classification tree with the selected characteristics.

Serum osteopontin (sOPN) and C reactive protein (CRP) in patients with giant cell arteritis (GCA) in remission according to treatment. (A) sOPN in patients.

(A) NKG2A and (B) NKG2C expression on NK cells in subjects with AS and HCs. The upper figure represents % of NK positive cells; the lower figure represents.

Secretion of TNF-α from macrophages and monocytic cells were reduced by the deletion of Nrdc. Secretion of TNF-α from macrophages and monocytic cells were.

Patient disposition over the 52-week study period

Network graph illustrating the relation between the assessed structural abnormalities on different locations within the knee joint in the total NEO study.

Joint pain location and severity.

Enhanced expression of Cap43 gene by nickel in breast cancer cell lines. Enhanced expression of Cap43 gene by nickel in breast cancer cell lines. Expression.

(A–F) Changes of B-cell numbers and B-cell related biomarkers.

Effect of bevacizumab on the proliferation of A2780 cells.

ACPA and RF titres in patients with early RA treated with abatacept+MTX compared with MTX alone. ACPA and RF titres in patients with early RA treated with.

Percent of patients with ASDAS inactive disease grouped by normal or elevated CRP at baseline through week 156. §p

Improvement in BASDAI score in patients with normal or elevated CRP at baseline through week 156. *p

proNGF and NGF activated different intracellular pathways.

Percentage of patients achieving remission by conversion to ACPA seronegative status. Percentage of patients achieving remission by conversion to ACPA.

NRDC and TNF-α increase in synovial fluid from patients with RA

Test of equal amplification efficiency of competitive PCR by titration of competitor. Test of equal amplification efficiency of competitive PCR by titration.

Changes in non-classical (CD11b+CD14+CD163−CD16+) and classical (CD11b+CD14+CD163+CD16−) monocytes over time in patients with rheumatoid arthritis (RA)

Presentation transcript:

IL-6-dependent changes in preclinical phase of arthritis in gp130F759. IL-6-dependent changes in preclinical phase of arthritis in gp130F759. Multiple parameters of WT, Il6KO (abbreviated as KO), gp130F759 (F759) and Il6KO/gp130F759 (KO/F759) at 5–6 months old (n=4 each) were examined. As systemic changes, (A) weight of the spleen, (B) serum titres of CRP, RF-IgM, and anti-CCP IgM are indicated at top. As a local changes in the joints, (C) Il6 gene expression by real time PCR, (D) the relative amounts of PAD4 protein by western blot {the average ratio of band densities (PAD4/β-actin) of WT=1.0} and (E) synovial cell numbers are indicated at bottom. Statistical significance was estimated by the Kruskal-Wallis test and Dunn’s method. ND; not detectable. CCP, circular citrullinated peptide; CRP, C reactive protein. Ayano Yahagi et al. RMD Open 2019;5:e000853 Copyright © BMJ Publishing Group & EULAR. All rights reserved.